# Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Study · id `cardio:ct-nct07227246` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07227246](<https://clinicaltrials.gov/study/NCT07227246>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07227246

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.

## Technical summary

Registry record NCT07227246. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-06 (actual); primary completion 2029-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT07227246, source copy `cardio:ctgov-nct07227246-2026-11-09`, retrieved 2026-11-18)
- Started: 2025-05-06 (actual) (ClinicalTrials.gov record NCT07227246, source copy `cardio:ctgov-nct07227246-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2029-01 (anticipated) (ClinicalTrials.gov record NCT07227246, source copy `cardio:ctgov-nct07227246-2026-11-09`, retrieved 2026-11-18)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07227246, source copy `cardio:ctgov-nct07227246-2026-11-09`, retrieved 2026-11-18)
- Countries: United States; Canada; Germany; Japan; Spain; United Kingdom (ClinicalTrials.gov record NCT07227246, source copy `cardio:ctgov-nct07227246-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07227246-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
- Acronym: FASTEST Part 2
- Condition: Intracerebral Hemorrhage
- Intervention (Biological): Recombinant Factor VIIa
- Intervention (Biological): Biological/Vaccine: Placebo
- Lead sponsor: Joseph Broderick, MD
- Lead sponsor class: OTHER
- Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator class: NIH
- Collaborator: Japan Agency for Medical Research and Development
- Collaborator class: OTHER\_GOV
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as a collaborator: National Institute of Neurological Disorders and Stroke (`cardio:ninds`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 30d9be44ef3ab76437c7d79d4ada510e41427035c24fd16e5d65bf60e159e334
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
